YS Biopharma Financial Statements From 2010 to 2024
| YSDelisted Stock | 0.48 0.03 5.88% |
Check YS Biopharma financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among YS Biopharma's main balance sheet or income statement drivers, such as , as well as many indicators such as . YS Biopharma financial statements analysis is a perfect complement when working with YS Biopharma Valuation or Volatility modules.
YS Biopharma |
YS Biopharma Co, Company Shares Outstanding Analysis
YS Biopharma's Outstanding Shares are shares of common stock of a public company that were purchased by investors after they were authorized and issued by the company to the public. Outstanding Shares are typically reported on fully diluted basis, including exotic instruments such as options, or convertibles bonds.
Current YS Biopharma Shares Outstanding | 188.33 M |
Most of YS Biopharma's fundamental indicators, such as Shares Outstanding, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, YS Biopharma Co, is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Outstanding shares that are stated on company Balance Sheet are used when calculating many important valuation and performance indicators including Return on Equity, Market Cap, EPS and many others.
CompetitionBased on the latest financial disclosure, YS Biopharma Co, has 188.33 M of shares currently outstending. This is 4.32% higher than that of the Biotechnology sector and 76.25% higher than that of the Health Care industry. The shares outstanding for all United States stocks is 67.07% higher than that of the company.
YS Biopharma Co, Fundamental Drivers Relationships
Comparative valuation techniques use various fundamental indicators to help in determining YS Biopharma's current stock value. Our valuation model uses many indicators to compare YS Biopharma value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across YS Biopharma competition to find correlations between indicators driving YS Biopharma's intrinsic value. More Info.YS Biopharma Co, is rated second in return on equity category among its peers. It is rated first in return on asset category among its peers . Comparative valuation analysis is a catch-all technique that is used if you cannot value YS Biopharma by discounting back its dividends or cash flows. It compares the stock's price multiples to nearest competition to determine if the stock is relatively undervalued or overvalued.About YS Biopharma Financial Statements
YS Biopharma shareholders use historical fundamental indicators, such as revenue or net income, to determine how well the company is positioned to perform in the future. Although YS Biopharma investors may analyze each financial statement separately, they are all interrelated. The changes in YS Biopharma's assets and liabilities, for example, are also reflected in the revenues and expenses on on YS Biopharma's income statement. Understanding these patterns can help investors time the market effectively. Please read more on our fundamental analysis page.
Thematic Opportunities
Explore Investment Opportunities
Check out Your Current Watchlist to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in state. You can also try the Equity Forecasting module to use basic forecasting models to generate price predictions and determine price momentum.
Other Consideration for investing in YS Biopharma Stock
If you are still planning to invest in YS Biopharma Co, check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the YS Biopharma's history and understand the potential risks before investing.
| Idea Optimizer Use advanced portfolio builder with pre-computed micro ideas to build optimal portfolio | |
| Bonds Directory Find actively traded corporate debentures issued by US companies | |
| FinTech Suite Use AI to screen and filter profitable investment opportunities | |
| Global Correlations Find global opportunities by holding instruments from different markets | |
| Portfolio Analyzer Portfolio analysis module that provides access to portfolio diagnostics and optimization engine | |
| Global Markets Map Get a quick overview of global market snapshot using zoomable world map. Drill down to check world indexes | |
| Latest Portfolios Quick portfolio dashboard that showcases your latest portfolios | |
| Portfolio Backtesting Avoid under-diversification and over-optimization by backtesting your portfolios | |
| Piotroski F Score Get Piotroski F Score based on the binary analysis strategy of nine different fundamentals |